Mirum Pharmaceuticals SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 26, 2026, 4:47 p.m. ETView on SEC.gov
Other events
AI summary, unreviewedMirum Pharmaceuticals Reports Positive Cohort 2 PROGRESS Results for ATEBRIOZ in Pediatric FOP Patients Aged 6 to <12 Years
8-KOct. 13, 2026, 8:09 a.m. ETView on SEC.gov
Other events
AI summary, unreviewedMirum Pharmaceuticals Phase 3 EXPAND Study of LIVMARLI Meets Primary Endpoint in Ultra-Rare Cholestatic Liver Diseases, Plans sNDA in 1H 2027
8-KSept. 28, 2026, 8:02 a.m. ETView on SEC.gov
Other events
8-KSept. 8, 2026, 8:34 a.m. ETView on SEC.gov
Departure/appointment of directors or officers
8-KAug. 5, 2026, 4:02 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits